Managing the effect of TRIPS on availability of priority vaccines

Bulletin of the World Health Organization

Volumn 84, Issue 5, 2006, Pages 360-365

  Milstien, Julie ^a   Kaddar, Miloud ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; ALUMINUM PHOSPHATE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MENINGITIS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; RECOMBINANT VACCINE; ROTAVIRUS VACCINE; VACCINE;

INFORMATION PROCESSING; INNOVATION; INTELLECTUAL PROPERTY RIGHTS; TECHNOLOGY TRANSFER; VACCINE; VIGILANCE;

CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG LEGISLATION; INFORMATION DISSEMINATION; INTERNATIONAL COOPERATION; LAW ENFORCEMENT; LICENSING; MARKETING; MEDICAL RESEARCH; MEDICAL SOCIETY; MEDICINE; ORGANIZATION AND MANAGEMENT; PATENT; PRODUCT DEVELOPMENT; TECHNOLOGY; WORLD HEALTH ORGANIZATION;

EID: 33646466515     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.05.028431     Document Type: Conference Paper

References (37)

1. World Trade Agreement and Public Health. World Trade Organization/World Health Organization. Geneva: WTO Secretariat; 2002.
2. World Trade Organization. Agreement on trade-related aspects of intellectual property rights. Geneva: WTO; 1995. Available from: http://www.wto.org/english/docs_e/legal_e/27-trips.pdf
3. Globalization and Access to Drugs. Perspectives on the WTO/TRIPS agreement. WHO/DAP/98.9 Revised. Geneva: World Health Organization; 1999.
4. World Trade Organization. Declaration on the TRIPS Agreement and Public Health, Ministerial Conference, Doha, Qatar. WT/MIN(01)/DEC/2. Geneva: WTO; 2001.
5. The General Council of the World Trade Organization. Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health: Decision of the General Council of 30 August, 2003. WT/L/540, 1 September 2003. Geneva: WTO; 2003. Available from: http://www.wto.org/english/tratop_e/trips_e/ implem_para6_e.htm
6. World Trade Organization. Members OK amendment to make health flexibility permanent. Press release. Press/426, 6 December 2005. Geneva: WTO; 2005. Available from: http://www.wto.org/english/news_e/pres05_e/pr426_e.htm
7. World Health Organization. Intellectual property rights and vaccines in developing countries. Report of a meeting 19-20 April 2004. Geneva: WHO; 2004. WHO document WHO/IVB/04.21. Available from: http://www.who.int/ intellectualproperty/events/vaccines_meeting/en/index.html
8. Mazzoleni R, Nelson RR. The benefits and costs of strong patent protection: a contribution to the current debate. Res Pol 1998;27;273-84.
9. Lanjouw JO, Cockburn I. New pills for poor people? Empirical evidence after GATT. World Dev 2001;29:265-89.
10. Shapiro RJ, Patents are part of the solution, not the problem. International Herald Tribune 2004, July 12.
11. Webber D, Kremer M. Perspectives on stimulating industrial research and development for neglected infectious disease. Bull World Health Organ 2001;79:735-41.
12. Commission on Health Research for Development. Health research, essential link to equity in development. New York: Oxford University Press; 1990.
13. Médecins sans Frontières Access to Essential Medicines Campaign and The Drugs for Neglected Diseases Working Group. Fatal imbalance: the crisis in research and development for drugs for neglected diseases. Geneva: MSF; 2001. Available from: http://www.accessmed-msf.org/prod/publications. asp?scntid=30112001115034&contenttype=PARA&
14. Garrison C. Background paper for the WHO Workshop on IP and Vaccines. 19-20 April, 2004. Geneva: WHO; 2004. Available from: http://www.who.int/ intellectualproperty/events/en/Background_paper.pdf
15. Jodar L, Laforce M, Ceccarini C, Aguado MT, Granoff D. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003;361:1902-4.
16. Grace C. The effect of changing intellectual property on pharmaceutical industry prospects in India and China: considerations for access to medicines. London: DfID Health Systems Resource Centre; June 2004. Available from http://www.dfid.gov.uk/pubs/files/indiachinadomproduce.pdf
17. Scherer M, Watal J. Post-TRIPS options for access to patented medicines in developing countries. Draft working paper for Working Group 4 of the Commission for Macroeconomics and Health. Geneva: World Health Organization; 2001
18. Kettler H, Modi R. Building local research and development capacity for the prevention and cure of neglected diseases: the case of India. Bull World Health Organ 2001;79:742-7.
19. Boston Consulting Group. Global Vaccine supply: the changing role of suppliers. A report commissioned for GAVI by WHO and the World Bank, 2005.
20. Widdus R. Public-private partnerships for health: their main targets, their diversity, and their future directions. Bull World Health Organ 2001;79:713-20.
21. University of New Hampshire Office of Intellectual Property Management. Bayh-Dole Act. Durham: University of New Hampshire; 2002. Available from: http://www.unh.edu/oipm/Bayhdole.htm
22. Malakoff D. NIH weighs demand to force sharing of AIDS drug patents. Science 2004;304:1427-9.
23. Heller MA, Eisenberg RS. Can patents deter innovation? The anticommons in biomedical research. Science 1998;280:698-701.
24. Smith RD, Thorsteinsdottir H, Daar AS, Gold ER, Singer PA. Economics knowledge and equity: a global public goods perspective of the patent system. Bull World Health Organ 2004;82:385-9.
25. Benkler Y. Commons-based strategies and the problem of patents. Science 2004;305:1110-1
26. Children's Vaccine initiative. Intellectual property protection: its role and benefits. Children's Vaccine Initiative. CVI/99.04. Geneva: World Health Organization; 1999.
27. DeRoeck D. Immunization financing in developing countries and the international vaccine market. Manila: Asian Development Bank; 2001. Available from: http://www.adb.org/Documents/Books/Immunization_ Financing/default.asp
28. Lambert J. Case Note Biogen Inc. v Medeva Plc. Huddersfield: Intellectual Property and Information Technology Update; 1997. Available from: http://www.ipit-update.com/pat05.htm
29. Takenaka T. Highly Anticipated UK Decision of Biogen v Medeva about validity of biotechnology patents. CASRIP Newsletter 1997;4:2. Available from: http://www.law.washington.edu/casrip/newsletter/Vol4/newsv4i2eu2.html
30. Mahoney R, Lee K, Yun Mikyung. Intellectual property, drug regulation, and building product innovation capability in biotechnology: the case of Hepatitis B vaccine in Korea, Innovation Strategy Today 2005;1:33-44. Available from: http://www.biodevelopments.org/innovation/index.htm
31. UNICEF Supply Division. Product Menu for Vaccines supplied by UNICEF for the Global Alliance for Vaccines and Immunization (GAVI), 4 December 2005. Available from: http://www.unicef.org/supply/files/GAVI_Product_Menu.pdf
32. World Health Organization. Globalization, TRIPS and access to pharmaceutical. WHO Policy Perspectives on Medicines No 3, March 2001. Geneva: WHO: 2001.
33. Kaplan WA, Laing R, Waning B, Levison L, Foster S. Is local production of pharmaceuticals a way to improve pharmaceutical access in developing and transitional countries? setting a research agenda. Draft paper, 23 April, 2003. Available from: http://www1.worldbank.org/hnp/hsd/documents/LOCALPRODUCTlON.pdf
34. Clark J, Piccolo J, Stanton B, Tyson K. Patent pools: a solution to the problem of access in biotechnology patents? Washington: United States Patent and Trademark Office; 2000.
35. Simon J. How patents may affect the development of a SARS vaccine: the possible role of patent pool Presentation at the second lunch time seminar of the WHO commission on Intellectual Property Rights, Innovation and Public Health, Geneva October 2004. Available from: http://www.who.int/ intellectualproperty/events/en/JamesSimon.pdf
36. Kreeftenberg JG, Hamidi A. Annex 5. Lessons learned in the transfer of Hib conjugate vaccine technology and the consequences for access to this vaccine in developing countries. Intellectual Property Rights and Vaccines in Developing Countries. WHO document WHO/IVB/04.21.
37. Commission on Intellectual Property Rights, Innovation and Public Health. Public health: innovation and intellectual property rights. WHO: Geneva; 2006. Available from: http://www.who.int/intelledualproperty/documents/thereport/ CIPIH23032006.pdf